Chris Raymond
Stock Analyst at Raymond James
(2.94)
# 1,322
Out of 5,172 analysts
9
Total ratings
66.67%
Success rate
54.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Chris Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNPR Monopar Therapeutics | Downgrades: Outperform | $142 → $123 | $55.21 | +122.79% | 3 | Nov 14, 2025 | |
| SION Sionna Therapeutics | Initiates: Strong Buy | $45 | $36.39 | +23.66% | 1 | Sep 3, 2025 | |
| TYRA Tyra Biosciences | Initiates: Strong Buy | $35 | $37.15 | -5.79% | 1 | Sep 3, 2025 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $94.77 | +10.79% | 1 | Sep 3, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Strong Buy | $23 | $6.56 | +250.61% | 1 | Sep 3, 2025 | |
| COGT Cogent Biosciences | Initiates: Strong Buy | $30 | $33.38 | -10.13% | 1 | Sep 3, 2025 | |
| BHVN Biohaven | Initiates: Strong Buy | $75 | $8.93 | +739.87% | 1 | Sep 3, 2025 |
Monopar Therapeutics
Nov 14, 2025
Downgrades: Outperform
Price Target: $142 → $123
Current: $55.21
Upside: +122.79%
Sionna Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $45
Current: $36.39
Upside: +23.66%
Tyra Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $35
Current: $37.15
Upside: -5.79%
Nuvalent
Sep 3, 2025
Initiates: Outperform
Price Target: $105
Current: $94.77
Upside: +10.79%
Kalaris Therapeutics
Sep 3, 2025
Initiates: Strong Buy
Price Target: $23
Current: $6.56
Upside: +250.61%
Cogent Biosciences
Sep 3, 2025
Initiates: Strong Buy
Price Target: $30
Current: $33.38
Upside: -10.13%
Biohaven
Sep 3, 2025
Initiates: Strong Buy
Price Target: $75
Current: $8.93
Upside: +739.87%